Related Experiment Video
Updated: Jun 29, 2025
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
Gut motility and hormone changes after bariatric procedures.
Khushboo Gala1, Wissam Ghusn2, Barham K Abu Dayyeh1
1Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Current Opinion in Endocrinology, Diabetes, and Obesity
|March 27, 2024
Summary
Metabolic and bariatric surgery (MBS) and endoscopic bariatric therapies (EBT) manage obesity through various mechanisms. Understanding these actions is crucial for refining treatments and improving patient care.
Area of Science:
- Gastroenterology
- Endocrinology
- Bariatric Medicine
Background:
- Obesity management increasingly involves metabolic and bariatric surgery (MBS) and endoscopic bariatric therapies (EBT).
- These interventions employ mechanisms such as restriction, malabsorption, and modulation of gastrointestinal hormones and motility.
Purpose of the Study:
- To review the mechanisms of action for MBS and EBT in obesity management.
- To highlight the importance of understanding these mechanisms for patient care and treatment refinement.
Main Methods:
- Review of current literature on MBS and EBT.
- Analysis of hormonal and motility changes associated with different bariatric procedures.
Main Results:
- Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) impact leptin, GLP-1, PYY, and ghrelin levels, altering gastric emptying and small bowel motility.
- Endoscopic sleeve gastroplasty (ESG) affects leptin, GLP-1, ghrelin, and PYY, with a notable effect on delaying gastric motility.
Conclusions:
- Understanding the distinct mechanisms of MBS and EBT is essential for optimizing patient outcomes.
- Further research into these mechanisms will facilitate the development of more refined and effective obesity treatments.
Related Concept Videos
01:40Hormonal Regulation
43.5K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.5K
01:20Gastrointestinal Motility Disorders
349
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
349
01:16Gastric Motility
694
Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
694
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
313
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
313
01:29Intestinal Phase of Digestion
5.2K
The intestinal phase of digestion is the third and final stage of the digestive process, occurring after the cephalic and gastric phases. It begins when chyme, a partially digested mixture of food and digestive enzymes, enters the small intestine from the stomach. This phase is crucial for nutrient absorption and involves complex hormonal and enzymatic interactions.
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
5.2K